Svc Pharma LP

Purdue Pharma L.p.

Euro-celtique S.a.

Ram Khanolkar

Gennady Nisnevich

Arie L Gutman

Igor Rukhman

Boris Pertsikov

Boris Tishin

Marina Etinger

Irina Fedotev

Gennady A Nisnevich

Gennady A Nisnevish

Methods for making trans-(&#x2212;)-&#x394;-tetrahydrocannabinol and trans-(+)-&#x394;-tetrahydrocannabinol are disclosed herein. In one embodiment, a trans-(&#x2212;)-&#x394;-tetrahydrocannabinol composition is prepared by allowing a composition comprising (&#xb1;)-&#x394;-tetrahydrocannabinol to separate on a chiral stationary phase to provide a trans-(&#x2212;)-&#x394;-tetrahydrocannabinol composition comprising at least about 99% by weight of trans-(&#x2212;)-&#x394;-tetrahydrocannabinol based on the total amount of trans-(&#x2212;)-&#x394;-tetrahydrocannabinol and trans-(+)-&#x394;-tetrahydrocannabinol. The invention also relates to methods for treating or preventing a condition such as pain comprising administering to a patient in need thereof an effective amount of a trans-(&#x2212;)-&#x394;-tetrahydrocannabinol having a purity of at least about 98% based on the total weight of cannabinoids.

[object Object]

Methods for making trans-(&#x2212;)-&#x394;-tetrahydrocannabinoI and trans-(+)-&#x394;-tetrahydrocannabinol are disclosed herein. In one embodiment, a trans-(&#x2212;)-&#x394;-tetrahydrocannabinoI composition is prepared by allowing a composition comprising (&#xb1;)-&#x394;-tetrahydrocannabinol to separate on a chiral stationary phase to provide a trans-(&#x2212;)-&#x394;-tetrahydrocannabinoI composition comprising at least about 99% by weight of trans-(&#x2212;)-&#x394;-tetrahydrocannabinol based on the total amount of trans-(&#x2212;)-&#x394;-tetrahydrocannabinol and trans-(+)-&#x394;-tetrahydrocannabinol. The invention also relates to methods for treating or preventing a condition such as pain comprising administering to a patient in need thereof an effective amount of a trans-(&#x2212;)-&#x394;-tetrahydrocannabinoI having a purity of at least about 98% based on the total weight of cannabinoids.

Methods for making trans-(&#x2212;)-&#x394;-tetrahydrocannabinol and trans-(+)-&#x394;-tetrahydrocannabinol are disclosed herein. In one embodiment, a trans-(&#x2212;)-&#x394;-tetrahydrocannabinol composition is prepared by allowing a composition comprising (&#xb1;)-&#x394;)-tetrahydrocannabinol to separate on a chiral stationary phase to provide a trans-(&#x2212;)-&#x394;-tetrahydrocannabinol composition comprising at least about 99% by weight of trans-(&#x2212;)-&#x394;-tetrahydrocannabinol based on the total amount of trans-(&#x2212;)-&#x394;-tetrahydrocannabinol and trans-(+)-&#x394;-tetrahydrocannabinol. The invention also relates to methods for treating or preventing a condition such as pain comprising administering to a patient in need thereof an effective amount of a trans-(&#x2212;)-&#x394;-tetrahydrocannabinol having a purity of at least about 98% based on the total weight of cannabinoids.

Growing community of inventors

Coventry, RI, United States of America

Ram Khanolkar